Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9.

Proc Natl Acad Sci U S A 2015 Apr 24;112(14):E1724-33. Epub 2015 Mar 24.

Laboratory of Cancer Biology and Genetics, Center for Cancer Research,

The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. Here, we show that the small ubiquitin-like modifier (SUMO) pathway is required for KRAS-driven transformation. RNAi depletion of the SUMO E2 ligase Ubc9 suppresses 3D growth of KRAS mutant colorectal cancer cells in vitro and attenuates tumor growth in vivo. In KRAS mutant cells, a subset of proteins exhibit elevated levels of SUMOylation. Among these proteins, KAP1, CHD1, and EIF3L collectively support anchorage-independent growth, and the SUMOylation of KAP1 is necessary for its activity in this context. Thus, the SUMO pathway critically contributes to the transformed phenotype of KRAS mutant cells and Ubc9 presents a potential target for the treatment of KRAS mutant colorectal cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1415569112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394293PMC
April 2015
20 Reads

Publication Analysis

Top Keywords

kras mutant
20
ligase ubc9
8
sumo pathway
8
mutant colorectal
8
mutant cells
8
sumo ligase
8
colorectal cancer
8
kras
6
mutant
5
subset proteins
4
cells subset
4
oncogenesis driven
4
vivo kras
4
proteins exhibit
4
exhibit elevated
4
sumoylation proteins
4
levels sumoylation
4
elevated levels
4
growth vivo
4
proteins kap1
4

References

(Supplied by CrossRef)

Similar Publications